Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
In this issue
Drug safety advice
- Natalizumab (Tysabri): risk of progressive multifocal leukoencephalopathy increases after two years of therapy.
- Fluoxetine: possible small risk of congenital cardiac defects, similar to that with paroxetine.
Stop press
- Sirolimus: different immunoassays for therapeutic drug monitoring—risk of incorrect dose adjustment.
Other information from the MHRA
- Drug Safety Update gains NHS Evidence accreditation.
- MHRA conference for doctors in training.
- Patient Information Leaflet of the month: Human Varicella-Zoster Immunoglobulin vaccine.
Drug Safety Update: Volume 3, Issue 8, March 2010 
